Biocon Joins March Into China With CMS

Biocon has joined the march of Indian firms into China, tying up with Chinese firm CMS to sell three generic formulations in the world’s second-largest drug market.

China_Painted_Flag
Three products will lead Biocon’s push into China • Source: Shutterstock

Biocon has become the latest Indian company to partner with a Chinese firm to enter the country’s fast-growing pharmaceutical market. The company has signed a license-and-supply deal with China Medical System Holdings Ltd, known as CMS, to sell three generic formulation products in the country. Biocon says opportunities from the fast-liberalizing Chinese drug market could be an important driver of future profit growth.

The total addressable market size is about $800m for the three products, Biocon said, citing IQVIA data. The company did...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Strategy

More from Business